Axsome Therapeutics 미래 성장

Future 기준 확인 6/6

Axsome Therapeutics (는) 각각 연간 58.1% 및 33.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 57.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 116.8% 로 예상됩니다.

주요 정보

58.1%

수익 성장률

57.8%

EPS 성장률

Pharmaceuticals 수익 성장	19.8%
매출 성장률	33.3%
향후 자기자본 수익률	116.8%
애널리스트 커버리지	Good
마지막 업데이트	29 Jan 2025

최근 미래 성장 업데이트

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Recent updates

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31

Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Dec 23

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

수익 및 매출 성장 예측

NasdaqGM:AXSM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	1,471	455	407	415	9
12/31/2026	1,033	130	180	167	13
12/31/2025	638	-118	-56	-75	16
12/31/2024	384	-262	-146	-207	16
9/30/2024	338	-311	-133	-133	N/A
6/30/2024	291	-309	-168	-167	N/A
3/31/2024	251	-296	-193	-193	N/A
12/31/2023	271	-239	-146	-145	N/A
9/30/2023	223	-202	-143	-142	N/A
6/30/2023	182	-184	-112	-111	N/A
3/31/2023	145	-159	-90	-90	N/A
12/31/2022	50	-187	-117	-117	N/A
9/30/2022	26	-160	-118	-118	N/A
6/30/2022	9	-150	-123	-122	N/A
3/31/2022	N/A	-141	-114	-114	N/A
12/31/2021	N/A	-130	-109	-108	N/A
9/30/2021	N/A	-126	-100	-100	N/A
6/30/2021	N/A	-114	-89	-89	N/A
3/31/2021	N/A	-100	-82	-82	N/A
12/31/2020	N/A	-103	-79	-78	N/A
9/30/2020	N/A	-99	-75	-75	N/A
6/30/2020	N/A	-95	-70	-70	N/A
3/31/2020	N/A	-90	-60	-60	N/A
12/31/2019	N/A	-68	-46	-46	N/A
9/30/2019	N/A	-53	-39	-39	N/A
6/30/2019	N/A	-42	-34	-34	N/A
3/31/2019	N/A	-37	-33	-33	N/A
12/31/2018	N/A	-31	-30	-30	N/A
9/30/2018	N/A	-29	-27	-27	N/A
6/30/2018	N/A	-27	N/A	-27	N/A
3/31/2018	N/A	-26	N/A	-27	N/A
12/31/2017	N/A	-29	N/A	-26	N/A
9/30/2017	N/A	-29	N/A	-27	N/A
6/30/2017	N/A	-30	N/A	-26	N/A
3/31/2017	N/A	-29	N/A	-24	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-23	N/A	-16	N/A
6/30/2016	N/A	-21	N/A	-13	N/A
3/31/2016	N/A	-16	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-7	N/A
6/30/2015	N/A	-6	N/A	-6	N/A
3/31/2015	N/A	-6	N/A	-5	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AXSM 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: AXSM (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: AXSM 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: AXSM 의 수익(연간 33.3% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: AXSM 의 수익(연간 33.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AXSM 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 116.8 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/29 08:09
장 마감 주가	2025/01/29 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Axsome Therapeutics, Inc. 26 애널리스트 중 16 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Joel Beatty	Baird
Esther Lannie Hong	Berenberg
Jason Matthew Gerberry	BofA Global Research

Axsome Therapeutics 미래 성장

Future 기준 확인 6/6

주요 정보

최근 미래 성장 업데이트

Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024

Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024

Consensus EPS estimates fall by 25%

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 21%

Recent updates

Axsome Therapeutics, Inc. to Report Q4, 2024 Results on Feb 18, 2025

Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024

Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Axsome Therapeutics, Inc. Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Axsome: AXS-07 And Its Upcoming Second PDUFA

Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Axsome Therapeutics: Lots Of Moving Parts

Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Consensus EPS estimates fall by 25%

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

COO & Secretary exercised options and sold US$1.9m worth of stock

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Independent Lead Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 12%, revenue upgraded

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Consensus revenue estimates increase by 45%

Consensus EPS estimates fall by 27%

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Price target increased to US$109

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Insufficient new directors

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Axsome Therapeutics: Clear Path Ahead For AXS07

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Forecast to breakeven in 2024